Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Mar 16;15:17588359231160141. doi: 10.1177/17588359231160141

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), 2023

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 3. — Detailed schematic of adaptive and acquired GDP-KRASG12C inhibitor resistance. The MAPK and PI3K/AKT pathways are shown here. Any protein in green indicates mRNA or protein upregulation after GDP-KRASG12C inhibitor (G12Ci) treatment, while any protein in red indicates any secondary mutation or copy number amplification that occurred after G12Ci treatment. Clinical trials investigating G12Ci combination therapies with targeted molecules against specific proteins are listed here. This schematic fails to address the resistance mechanisms including but not limited to histologic transformation, genetic rearrangements, immunomodulation, or global proteome changes in metabolic programming.